Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 9/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.42 |
| ▸ | RET | P07949 | 9/20 | 0.41 |
| ▸ | ROS1 | P08922 | 9/20 | 0.41 |
| ▸ | FLT3 | P36888 | 9/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468621 | 0.91 | L3MBTL3 (0.43) | — | |
| SCHEMBL467696 | 0.88 | AXL (0.43) | ALKEGFRFGFR3ACVR1VCP | |
| SCHEMBL467634 | 0.79 | ACVR1 (0.41) | FLT3FGFR3PDGFRBPDGFRAACVR1 | |
| SCHEMBL30090827 | 0.79 | ACVR1 (0.41) | FLT3FGFR3PDGFRBPDGFRAACVR1 | |
| SCHEMBL467659 | 0.78 | AXL (0.49) | — | |
| SCHEMBL467478 | 0.77 | AXL (0.42) | — | |
| SCHEMBL10035939 | 0.77 | MAPT (0.56) | EML4ALKRETROS1FLT3 | |
| SCHEMBL467749 | 0.77 | AXL (0.40) | ACVR1VCP | |
| SCHEMBL28039190 | 0.76 | L3MBTL3 (0.42) | — | |
| SCHEMBL467601 | 0.76 | FLT3 (0.36) | FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-2387395-A1 | AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER | Rigel Pharmaceuticals, Inc. (US) | 2011-11-23 | — | — | EP | disclosed |
| US-8040491-B2 | Exposure method, substrate stage, exposure apparatus, and device manufacturing method | NIKON CORPORATION (JP) | 2011-10-18 | — | — | US | disclosed |
| CN-101622246-A | Polycyclic heteroaryl substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC | 2010-01-06 | — | — | CN | disclosed |